Vanicoside B
Based on 1 publication(s) in Google Scholar
Vanicoside B is a phenylpropanoyl sucrose derivative, can be isolated from the herb Persicaria dissitiflora. Vanicoside B targets cyclin-dependent kinase 8 (CDK8) and exhibits anti-tumor activity. The potential mechanism is Vanicoside B blocks CDK8-mediated signaling pathways and decreases the expression of epithelial-mesenchymal transition proteins, so that it leads to cell cycle arrest and apoptosis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.82%
- CAS No.: 155179-21-8
- Formule: C49H48O20
- Masse moléculaire:956.89
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Vanicoside B
More
Activité biologique
|
CDK3 |
STAT3 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-231 | IC50 |
9 μM
Compound: 2
|
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability after 72 hrs by SRB assay
|
[PMID: 31622095] |
Vanicoside B (2.5-20 μM; 72 h) shows antiproliferative activity against a panel of cancer cell lines in triple-negative breast cancer (TNBC) MDA-MB-231 cells and HCC38 cells[1].
Vanicoside B (2.5-20 μM; 72 h, 14 d, and 72 h, respectively) inhibits cell viability, colony formation, and disturbs cell cycle distribution in TNBC cells[1].
Vanicoside B (2.5-10 μM; 48 h) decreased p-STAT1, p-STAT3, and p-S6 protein level, and induces apoptosis by regulating the Skp2-p27 axis in TNBC cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231 cells and HCC38 cells
-
Concentration:0, 2.5, 5, 10 μM
-
Incubation Time:48 hours
-
Result:Increased cleaved PARP, and p27 protein expressions, but decreased Skp2 protein level.
Suppressed CDK8 target genes and the expression of EMT-associated proteins.
Suppressed the expression of the cell proliferation marker Ki-67 in tumor tissues, also significantly suppressed the expressions of p-STAT1 (S727) and AXL.
-
Cell Line:MDA-MB-231 cells and HCC38 cells
-
Concentration:0, 2.5, 5, 10 μM
-
Incubation Time:72 hours
-
Result:Inhibited cell cycle at sub-G1 phase.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:MDA-MB-231 cell-implanted xenograft mouse model[1]
-
Dosage:5 mg/kg, 20 mg/kg
-
Administration:Intraperitoneal injection; 3 times per week over 4 weeks
-
Result:Significantly reduced tumor volumes at 5 mg/kg and 20 mg/kg by 53.85% and 65.72%, respectively.
Chemical Information
-
CAS No. 155179-21-8
-
Appearance Solid
-
Masse moléculaire 956.89
-
Formule C49H48O20
-
Color White to off-white
-
SMILES
OC(C=C1)=CC=C1/C=C/C(OC[C@@]2([C@H]([C@@H]([C@H](O2)COC(/C=C/C3=CC=C(C=C3)O)=O)O)OC(/C=C/C4=CC=C(C=C4)O)=O)O[C@H]5O[C@@H]([C@H]([C@@H]([C@H]5O)O)O)COC(/C=C/C6=CC(OC)=C(C=C6)O)=O)=O
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Plants
Analysis of Phenolic Compounds of Reynoutria sachalinensis and Reynoutria japonica Growing in the Russian Far East. [Abstract]2024 Nov 27;13(23):3330. PMID: 39683123
Solvant et solubilité
DMSO : 100 mg/mL (104.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.61 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Kim D, et al. Antitumor Activity of Vanicoside B Isolated from Persicaria dissitiflora by Targeting CDK8 in Triple-Negative Breast Cancer Cells. J Nat Prod. 2019 Nov 22;82(11):3140-3149. [Content Brief]
[2]. Takasaki M, et al. Cancer chemopreventive activity of phenylpropanoid esters of sucrose, vanicoside B and lapathoside A, from Polygonum lapathifolium. Cancer Lett. 2001 Nov 28;173(2):133-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.0451 mL | 5.2253 mL | 10.4505 mL | 26.1263 mL |
| 5 mM | 0.2090 mL | 1.0451 mL | 2.0901 mL | 5.2253 mL | |
| 10 mM | 0.1045 mL | 0.5225 mL | 1.0451 mL | 2.6126 mL | |
| 15 mM | 0.0697 mL | 0.3484 mL | 0.6967 mL | 1.7418 mL | |
| 20 mM | 0.0523 mL | 0.2613 mL | 0.5225 mL | 1.3063 mL | |
| 25 mM | 0.0418 mL | 0.2090 mL | 0.4180 mL | 1.0451 mL | |
| 30 mM | 0.0348 mL | 0.1742 mL | 0.3484 mL | 0.8709 mL | |
| 40 mM | 0.0261 mL | 0.1306 mL | 0.2613 mL | 0.6532 mL | |
| 50 mM | 0.0209 mL | 0.1045 mL | 0.2090 mL | 0.5225 mL | |
| 60 mM | 0.0174 mL | 0.0871 mL | 0.1742 mL | 0.4354 mL | |
| 80 mM | 0.0131 mL | 0.0653 mL | 0.1306 mL | 0.3266 mL | |
| 100 mM | 0.0105 mL | 0.0523 mL | 0.1045 mL | 0.2613 mL |
Vanicoside B Related Classifications
HY-N9561 Related Classifications
Powered by Bioz